Clinical DevelopmentThe company has aligned with FDA on requirements for ongoing phase 2 AQUAx2 clinical trial, which supports potential BLA filing and adds another asset to watch.
Financial ForecastMultiple partnerships have bolstered the company's cash position, providing a solid financial foundation for near-term operations.
Strategic InvestmentThe company has secured a strategic investment from Sanofi and an asset purchase agreement with Janssen, enhancing the financial stability and future growth prospects.